Evidence map›Paper›PMID 38503849›Full record

ArticleArchives of gynecology and obstetrics2024

Comparison between oral dydrogesterone versus micronized vaginal progesterone gel in clinical outcome within the first HRT-FET cycle: a retrospective analysis.

Tian-Min Ye, Long-Dan Luo, Yuan-Fei Huang, Shufang Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Reproductive outcome after frozen embryo transfer with hormone replacement therapy according to luteal-phase support protocol: systematic review and network meta-analysis of randomized controlled trials.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025
    Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Tian-Min YeCenter of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China. yetm@hku-szh.org.ORCID http://orcid.org/0009-0008-6690-0075
Long-Dan LuoCenter of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.
Yuan-Fei HuangCenter of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.
Shufang DingCenter of Reproductive Medicine, The University of Hong Kong-Shenzhen Hospital, No.1, Haiyuan Road, Shenzhen City, Guangdong Province, The People's Republic of China.
Shenzhen University · CNUniversity of Hong Kong - Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this study is to compare the clinical efficacy of oral dydrogesterone and micronized vaginal progesterone (MVP) gel during the first HRT-FET cycle.

methodsA retrospective cohort study based on a total of 344 women undergoing their first HRT-FET cycles without Gonadotropin-Releasing Hormone agonist (GnRH-a) pretreatment was conducted. All the cycles were allocated to two groups in the reproductive medical center at the University of Hong Kong-Shenzhen Hospital. One group (n = 193) received oral dydrogesterone 30 mg/d before embryo transfer, while the other group (n = 151) received MVP gel 180 mg/d.

resultsThe demographics and baseline characteristics of two groups were comparable. We found no statistically significant difference in live birth rate (24.35% vs. 31.13%, P = 0.16), clinical pregnancy rate (34.72% vs. 36.42%, P = 0.74), embryo implantation rate (25.09% vs. 28.36%, P = 0.43), positive pregnancy rate (42.49% vs 38.41%, P = 0.45), miscarriage rate (9.33% vs 3.97%, P = 0.05), or ectopic pregnancy rate (0.52% vs. 0.66%, P = 0.86) between the oral dydrogesterone group and MVP gel group. In the multivariate logistic regression analysis for covariates, medication used for luteal support was not associated with live birth rate (OR = 0.73, 95% CI: 0.32-1.57, P = 0.45). And the different luteal support medication did not have a significant positive association with the live birth rate in the cycles with day 2 embryo transferred (OR = 1.39, 95% CI:0.66-2.39, P = 0.39) and blastocyst transferred (OR = 1.31 95% CI:0.64-2.69, P = 0.46).

conclusion30 mg/d oral dydrogesterone and 180 mg/d MVP gel revealed similar reproductive outcomes in HRT-FET cycles in the study.

Indexed as

DydrogesteroneProgesteroneEmbryo TransferFemaleHumansLuteinPregnancyPregnancy RateRetrospective StudiesDydrogesteroneLuteinProgesteroneDydrogesterone (DYD)Frozen-thawed Embryo Transfer (FET)Hormone Replacement Treatment (HRT)Luteal phase support (LPS)Micronized vaginal progesterone gel (MVP)

Identifiers

PMID38503849
OpenAlexW4392942530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.